{"entity":{"id":"nct06423911","kind":"trial","name":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","aka":["POLARIS-2"],"tldr":"A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.","summary":"Study of Olverembatinib (HQP1351) in Patients With CML-CP is a phase 3 interventional study registered as NCT06423911 by Ascentage Pharma Group Inc., with 333 participants planned, started 2024-02-05. Conditions listed: Chronic Myeloid Leukemia, CML, CML, Chronic Phase. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06423911","url":"https://clinicaltrials.gov/study/NCT06423911"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cml","cml-chronic-phase"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["olverembatinib"],"companies":["ascentage-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06423911","phase":"3","setting":"A Global, Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML-CP)","sponsor":"Ascentage Pharma Group Inc.","participation":[{"nct":"NCT06423911","source":"https://clinicaltrials.gov/study/NCT06423911","fetchedAt":"2026-10-07T16:54:39.727Z","studySha256":"1fcec41073170fb7e1cc924ce094f9951fc241a8dae79bfa3c942d750e139ada","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-15","leadSponsor":"Ascentage Pharma Group Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":333,"enrolmentType":"ESTIMATED","siteCount":163,"recruitingSiteCount":135,"countries":["Australia","Belgium","Canada","France","Germany","India","Italy","Japan","Poland","Russia","Singapore","South Korea","Spain","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2024-02-05","startedType":"actual","enrolled":333,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06423911/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"cml-chronic-phase","kind":"cancer","name":"Chronic myeloid leukaemia, chronic phase","route":"/cancers/cml-chronic-phase/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"olverembatinib","kind":"drug","name":"Olverembatinib","route":"/drugs/olverembatinib/"}],"company":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/"}]}}